Csl Ltd (QX) News - CSLLY

Haemonetics and CSL Plasma Announce a Long-Term Plasma Collection Software Agreement

Haemonetics and CSL Plasma Announce a Long-Term Plasma Collection Software Agreement PR Newswire BRAINTREE, Mass. and BOCA RATON, Fla., March 5...

CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of ...

CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia CSL...

U.S. FDA Accepts for Review CSL Behring's Biologics License Application for rIX-FP for Hemophilia B Patients

U.S. FDA Accepts for Review CSL Behring's Biologics License Application for rIX-FP for Hemophilia B Patients PR Newswire KING OF PRUSSIA, Pa...

FDA Approves New Dosing Option for CSL Behring's Hizentra®

FDA Approves New Dosing Option for CSL Behring's Hizentra® New Label Supports Individualized Therapy Through Greater Dosing Flexibility From...

CSL Behring Submits Biologics License Application for FDA Approval of Recombinant Fusion Protein Linking Coagulation Factor I...

CSL Behring Submits Biologics License Application for FDA Approval of Recombinant Fusion Protein Linking Coagulation Factor IX with Recombinant...

CSL Issues "Our Corporate Responsibility 2014" Report

CSL Issues "Our Corporate Responsibility 2014" Report Led by CSL Behring performance, the company focuses on sustainable business...

CMS Extends New Technology Add-On Payment for CSL Behring's Kcentra®

CMS Extends New Technology Add-On Payment for CSL Behring's Kcentra® Designation Helps Improve Patient Access to Kcentra in the Inpatient...

Evidence presented at the 16th Biennial Meeting of the European Society for Immunodeficiencies (ESID) Supports Individualized...

Evidence presented at the 16th Biennial Meeting of the European Society for Immunodeficiencies (ESID) Supports Individualized Dosing with...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Csl Ltd (QX) (CSLLY)

Empower your portfolio: Real-time discussions and actionable trading ideas.

CSLLY News

Haemonetics and CSL Plasma Announce a Long-Term Plasma Collection Software Agreement

CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of ...

U.S. FDA Accepts for Review CSL Behring's Biologics License Application for rIX-FP for Hemophilia B Patients

FDA Approves New Dosing Option for CSL Behring's Hizentra®

CSL Behring Submits Biologics License Application for FDA Approval of Recombinant Fusion Protein Linking Coagulation Factor I...

CSL Issues "Our Corporate Responsibility 2014" Report

CMS Extends New Technology Add-On Payment for CSL Behring's Kcentra®

Evidence presented at the 16th Biennial Meeting of the European Society for Immunodeficiencies (ESID) Supports Individualized...

CSL Behring Announces Winners of its 13th Annual Gettin' in the Game(SM) Junior National Championship Program

CSL Behring Signs Strategic Development Agreement With Enable Injections To Market Novel New Drug Delivery Device

CSL Behring Signs Strategic Development Agreement With Enable Injections To Market Novel New Drug Delivery Device

CSL to acquire Novartis' influenza vaccine business

Plasma Donors Recognized During International Plasma Awareness Week For Helping Save Lives

CSL Behring Launches $450 Million Capacity Expansion To Meet Growing Need For Lifesaving, Life-improving Therapies

CSL Behring Expands Manufacturing Facility In Kankakee, Illinois To Meet Patients' Growing Needs

CSLLY Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Csl Ltd (QX) (CSLLY) News

Csl Ltd (QX) (CSLLY)

Empower your portfolio: Real-time discussions and actionable trading ideas.

CSLLY News

Haemonetics and CSL Plasma Announce a Long-Term Plasma Collection Software Agreement

CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of ...

U.S. FDA Accepts for Review CSL Behring's Biologics License Application for rIX-FP for Hemophilia B Patients

FDA Approves New Dosing Option for CSL Behring's Hizentra®

CSL Behring Submits Biologics License Application for FDA Approval of Recombinant Fusion Protein Linking Coagulation Factor I...

CSL Issues "Our Corporate Responsibility 2014" Report

CMS Extends New Technology Add-On Payment for CSL Behring's Kcentra®

Evidence presented at the 16th Biennial Meeting of the European Society for Immunodeficiencies (ESID) Supports Individualized...

CSL Behring Announces Winners of its 13th Annual Gettin' in the Game(SM) Junior National Championship Program

CSL Behring Signs Strategic Development Agreement With Enable Injections To Market Novel New Drug Delivery Device

CSL Behring Signs Strategic Development Agreement With Enable Injections To Market Novel New Drug Delivery Device

CSL to acquire Novartis' influenza vaccine business

Plasma Donors Recognized During International Plasma Awareness Week For Helping Save Lives

CSL Behring Launches $450 Million Capacity Expansion To Meet Growing Need For Lifesaving, Life-improving Therapies

CSL Behring Expands Manufacturing Facility In Kankakee, Illinois To Meet Patients' Growing Needs

CSLLY Discussion

Your Recent History